Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Irbesartan does not influence the antiplatelet effect of aspirin in spontaneously hypertensive rats.

Hu GL, Leng WX, Wang X, Lu XC, Liu AJ, Cui H, Cao J, Fan L.

CNS Neurosci Ther. 2012 Aug;18(8):709-10. doi: 10.1111/j.1755-5949.2012.00350.x. No abstract available.

PMID:
22742580
2.

Losartan does not influence the blood platelet aggregation in normotensive rats.

Chabielska E, Pawlak R, Buczko W.

Acta Physiol Hung. 1996;84(3):271-2.

PMID:
9219602
3.

Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.

Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA.

Fundam Clin Pharmacol. 2003 Feb;17(1):83-91.

PMID:
12588634
4.

Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood.

Kariyazono H, Nakamura K, Arima J, Ayukawa O, Onimaru S, Masuda H, Iguro Y, Majima HJ, Sakata R, Yamada K.

Blood Coagul Fibrinolysis. 2004 Mar;15(2):157-67.

PMID:
15091003
5.
6.

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, Danser AH.

J Hypertens. 2010 Oct;28(10):2145-55. doi: 10.1097/HJH.0b013e32833d01ae.

PMID:
20625318
9.

Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.

Alexandru N, Popov D, Dragan E, Andrei E, Georgescu A.

J Thromb Haemost. 2011 Jan;9(1):173-84. doi: 10.1111/j.1538-7836.2010.04122.x.

10.

Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.

Dai HY, Zheng M, Tang RN, Ni J, Ma KL, Li Q, Liu BC.

Am J Med Sci. 2011 Mar;341(3):207-14. doi: 10.1097/MAJ.0b013e3182010da9.

PMID:
21326079
11.

Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats.

Behrend EN, Grauer GF, Greco DS, Rose BJ, Thrall MA.

J Am Anim Hosp Assoc. 1996 Jan-Feb;32(1):11-8.

PMID:
8963730
12.

Synthesis and anti-platelet activity of obovatol derivatives.

Kwak JH, Lee S, Park ES, In JK, Song J, Kim YJ, Choi NS, Lee H, Yun YP, Hong JT, Kwak YS, Min KH, Jung JK.

Arch Pharm Res. 2011 Jul;34(7):1107-12. doi: 10.1007/s12272-011-0708-9.

PMID:
21811917
13.

AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.

Cediel E, de Las Heras N, Sanz-Rosa D, Velasco O, Cachofeiro V, Lahera V.

Kidney Int Suppl. 2005 Jan;(93):S3-9.

PMID:
15613065
14.

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.

Circulation. 2007 Jun 26;115(25):3156-64.

16.
17.

Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.

Renda G, Zurro M, Malatesta G, Ruggieri B, De Caterina R.

Haematologica. 2010 Dec;95(12):2095-101. doi: 10.3324/haematol.2010.027102.

18.

Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.

Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE.

Clin Pharmacokinet. 2008;47(2):129-37.

PMID:
18193919
19.
20.

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.

Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C.

J Clin Pharmacol. 2005 Oct;45(10):1172-8.

PMID:
16172182
Items per page

Supplemental Content

Support Center